Tokyo, Japan, Japan · Est. 2005 · 20,000 employees
Astellas Pharma is a Japanese pharmaceutical company focused on innovative treatments in oncology, immunology, and other therapeutic areas through research and development.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 8 drugs with upcoming expirations
Pipeline
By Phase
11 drugs in development
By Therapeutic Area
top 6
R&D Momentum
77/100
Pipeline Velocity
50/100
Trial Completion Rate
91/100
Pipeline Concentration
17/100
Pipeline Freshness
70/100
Strategic Signals
Activity
Last 14 days
A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)
A Phase 1, Open-label Study to Evaluate the Metabolism and Excretion of [14C]ASP3082 in Healthy Adult Male Participants
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)
A Phase 3, Single-arm, 12-week Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Indian Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications
A Phase 1b, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Subretinal Dose of ASP2020 in Participants With Macular Dystrophies With a Stargardt-type Clinical Presentation
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer
Details
Company Overview
$55.0B
Mkt Cap
$13.2B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Myrbetriq — MYRBETRIQ
Application NDA202611
Myrbetriq — MYRBETRIQ
Application NDA202611
Lexiscan — LEXISCAN
Application NDA022161
Xospata — XOSPATA
Application NDA211349 (NDA)
Lexiscan — LEXISCAN
Application NDA022161
Myrbetriq — MYRBETRIQ
Application NDA202611
Xtandi — XTANDI
Application NDA213674 (NDA)
VESIcare — VESICARE LS
Application NDA209529 (NDA)
Myrbetriq — MYRBETRIQ GRANULES
Application NDA213801 (NDA)
Myrbetriq — MYRBETRIQ
Application NDA202611
Myrbetriq — MYRBETRIQ GRANULES
Application NDA213801
Cresemba — CRESEMBA
Application NDA207500 (NDA)
Izervay — IZERVAY
Application NDA217225 (NDA)
Veozah — VEOZAH
Application NDA216578 (NDA)
Veozah — VEOZAH
Application NDA216578
Veozah — VEOZAH
Application NDA216578
VYLOY — VYLOY
Application BLA761365 (BLA)
VYLOY — VYLOY
Application BLA761365
Veozah — VEOZAH
Application NDA216578
VYLOY — VYLOY
Application BLA761365
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)